Synthesis and pharmacological evaluation of nucleoside prodrugs designed to target siderophore biosynthesis in Mycobacterium tuberculosis
- 1 March 2016
- journal article
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 24 (6) , 1314-1321
Abstract
No abstract availableKeywords
Funding Information
- NIH (AI070219)
This publication has 21 references indexed in Scilit:
- Synthesis and Pharmacokinetic Evaluation of Siderophore Biosynthesis Inhibitors forMycobacterium tuberculosisJournal of Medicinal Chemistry, 2015
- Prodrugs of nucleoside analogues for improved oral absorption and tissue targetingJournal of Pharmaceutical Sciences, 2008
- Prodrugs: design and clinical applicationsNature Reviews Drug Discovery, 2008
- 5‘-O-[(N-Acyl)sulfamoyl]adenosines as Antitubercular Agents that Inhibit MbtA: An Adenylation Enzyme Required for Siderophore Biosynthesis of the MycobactinsJournal of Medicinal Chemistry, 2007
- Determination of drug permeability and prediction of drug absorption in Caco-2 monolayersNature Protocols, 2007
- Antitubercular Nucleosides That Inhibit Siderophore Biosynthesis: SAR of the Glycosyl DomainJournal of Medicinal Chemistry, 2006
- Inhibition of aryl acid adenylation domains involved in bacterial siderophore synthesisThe FEBS Journal, 2005
- Rationally Designed Nucleoside Antibiotics That Inhibit Siderophore Biosynthesis of Mycobacterium tuberculosisJournal of Medicinal Chemistry, 2005
- Small-molecule inhibition of siderophore biosynthesis in Mycobacterium tuberculosis and Yersinia pestisNature Chemical Biology, 2005
- Pivalate-Generating Prodrugs and Carnitine Homeostasis in ManPharmacological Reviews, 2002